3.095  -0.025 (-0.8%)		01-14 13:04
Open: 3.17 High: 3.17 Volume: 371,662		Pre. Close: 3.12 Low: 2.98 Market Cap: 61(M)

Short term
Mid term
Targets	6-month :	4.67	1-year :	5.41
Resists	First :	4	Second :	4.63
Pivot price	3.59
Supports	First :	2.97	Second :	2.47
MAs	MA(5) :	3.45	MA(20) :	3.63
	MA(100) :	2.86	MA(250) :	2.58
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	14.1	D(3) :	28.8
RSI	RSI(14): 38.4
52-week	High :	5.5	Low :	1.11

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ANVS ] has closed above bottom band by 2.7%. Bollinger Bands are 5.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.54 - 3.56	3.56 - 3.58
Low:	2.94 - 2.97	2.97 - 3
Close:	3.08 - 3.12	3.12 - 3.15

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Thu, 18 Dec 2025
Annovis Bio to Launch Long-Term Open-Label Study for Buntanetap in Parkinson's Disease Patients Starting January 2026 - Quiver Quantitative

Tue, 16 Dec 2025
Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewswire

Wed, 10 Dec 2025
Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough? - RTTNews

Mon, 24 Nov 2025
Annovis Bio (NYSE: ANVS) to share two CTAD 2025 presentations on buntanetap - Stock Titan

Mon, 24 Nov 2025
Annovis Announces Two Presentations at the CTAD 2025 Conference - GlobeNewswire

Tue, 18 Nov 2025
FDA schedules meeting with Annovis Bio on Parkinson’s disease dementia - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Biotechnology
Shares Out	27 (M)
Shares Float	22 (M)
Held by Insiders	15.4 (%)
Held by Institutions	11.5 (%)
Shares Short	2,860 (K)
Shares Short P.Month	1,310 (K)

EPS	-1.43
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.64
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-105.9 %
Return on Equity (ttm)	-246.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-25 (M)
Levered Free Cash Flow	-16 (M)

PE Ratio	-2.18
PEG Ratio	0
Price to Book value	4.78
Price to Sales	0
Price to Cash Flow	-3.3

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.